摘要
目的:探讨参苓白术胶囊对脾虚湿阻证溃疡性结肠炎(UC)和类风湿关节炎(RA)大鼠“异病同治”的作用机制。方法:采用“饮食不节+劳倦过度+高湿环境”制备脾虚湿阻证大鼠模型;第11周,采用Ⅱ型胶原诱导RA模型;第12周,采用灌肠(30%乙醇0.25 mL+TNBS 0.2 mL/100 g)制备UC模型。造模成功后,采用参苓白术胶囊(200、400和800 mg/kg)干预。检测代谢、体重、脏器系数、小肠推进率、胃排空率、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平;采用酶联免疫吸附试验测定血清胃泌素、胃动素、肿瘤坏死因子α(TNF-α)、白细胞介素(IL)1β和IL-6水平;采用苏木精-伊红(HE)染色观察结肠和踝关节的病变情况。结果:(1)与脾虚湿阻证UC大鼠相比,采用参苓白术胶囊治疗后,大鼠的毛发状态改善、柔顺光泽,进食量、粪便量和活跃度增加,肝脏系数降低,小肠推进率升高,血清TC、IL-6和IL-1β水平降低,血清HDL-C和胃泌素水平升高,隐血改善,结肠壁结构恢复、炎症细胞浸润减轻。(2)与脾虚湿阻证RA大鼠相比,采用参苓白术胶囊治疗后,大鼠的毛发情况改善、柔顺光泽,进食量和活跃度增加,肝脏系数降低,胸腺系数升高,小肠推进率升高,血清TC、LDL-C和TNF-α水平降低,血清胃动素和胃泌素水平升高,关节肿胀改善,关节腔结构恢复、炎症细胞浸润减轻。结论:参苓白术胶囊能“异病同治”脾虚湿阻证UC和RA大鼠,改善大鼠肠黏膜损伤和关节炎,其机制与改善炎症反应有关。
OBJECTIVE:To probe into the mechanism of Shenlingbaizhu capsule in the treatment of ulcerative colitis(UC)and rheumatoid arthritis(RA)with spleen deficiency and dampness obstruction syndrome through“homotherapy for heteropathy”.METHODS:The rat model of spleen deficiency and dampness obstruction syndrome was established by“improper diet+excessive fatigue+high humidity environment”.At the 10th week of the experiment,the rats were treated with Shenlingbaizhu capsule(200,400 and 800 mg/kg);At the 11th week,the RA model was induced by type Ⅱ collagen;at the 12th week,the UC model was established by enema(30% ethanol 0.25 mL+0.2 mL/100 g TNBS).After successful modeling,the rats were treated with Shenlingbaizhu capsule(200,400 and 800 mg/kg).The metabolic condition,body weight,organ index,small intestinal propulsion rate,gastric emptying rate,total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)were detected.The levels of serum gastrin,motilin,tumor necrosis factor-α(TNF-α),interleukin(IL)-1βand IL-6 were determined by enzyme-linked immunosorbent assay.Hematoxylin-Eosin(HE)staining was used to observe the pathological changes in the colon and ankle joints.RESULTS:(1)Compared with UC rats with spleen deficiency and dampness obstruction syndrome,after treatment with Shenlingbaizhu capsule,the hair condition of rats was improved,becoming more lustrous and smooth;the food intake,fecal volume and activity level increased,while the liver coefficient decreased,the small intestine propulsion rate increased,the contents of serum TC,IL-6 and IL-1βdecreased,the levels of serum HDL-C and gastrin increased,the occult blood was improved,the structure of the colon wall was recovered and the inflammatory infiltration was alleviated.(2)Compared with RA rats with spleen deficiency and dampness obstruction syndrome,the hair condition was improved after treatment with Shenlingbaizhu capsule,becoming more lustrous and smooth;the food intake,fecal volume and activity level increased,while the liver coefficient decreased,the thymus coefficient increased,the small intestine propulsion rate increased,the contents of serum TC,LDL-C and TNF-α decreased,the contents of serum motilin and gastrin increased,the joint swelling was improved,and the joint cavity structure was recovered,with reduced inflammatory infiltration.CONCLUSIONS:The efficacy of Shenlingbaizhu capsule in the treatment of UC and RA with spleen deficiency and dampness obstruction syndrome through“homotherapy for heteropathy”is significant,which can improve intestinal mucosal damage and arthritis in the rats,and the mechanism is related to the alleviation of inflammatory responses.
作者
苏祖清
叶泽婷
陈海明
唐斌
李彦霖
郑旭威
江涛
黄闰月
郑广娟
卢传坚
SU Zuqing;YE Zeting;CHEN Haiming;TANG Bin;LI Yanlin;ZHENG Xuwei;JIANG Tao;HUANG Runyue;ZHENG Guangjuan;LU Chuanjian(State Key Laboratory of Traditional Chinese Medicine Syndrome,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;State Key Laboratory of Dampness Syndrome of Chinese Medicine,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;Guangdong-Hong Kong-Macao Joint Lab on Chinese Medicine and Immune Disease Research,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;Guangdong Provincial Clinical Research Center for Chinese Medicine Dermatology,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co.,Ltd.,Guangzhou 510130,China)
出处
《中国医院用药评价与分析》
2025年第7期779-785,共7页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
国家自然科学基金资助项目(No.U20A20397,No.U23A6012)
省部共建中医湿证国家重点实验室专项(No.SZ2021ZZ45,No.SZ2021ZZ15)
广州市科技计划项目重点研发计划(No.202206080006)
中医药治疗难治性自身免疫病传承创新团队(No.ZYYCXTD-C-202204)
广州市科技计划项目(No.2024A03J0702,No.2024A03J0707)
中医证候全国重点实验室项目(No.QZ2023ZZ39)。
关键词
脾虚湿阻证
溃疡性结肠炎
类风湿关节炎
参苓白术胶囊
炎症反应
Spleen deficiency and dampness obstruction syndrome
Ulcerative colitis
Rheumatoid arthritis
Shenlingbaizhu capsule
Inflammatory response
